-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 28, 2021, AbbVie announced that ABBV-951 (foslevodopa/foscarbidopa), a treatment for Parkinson’s disease under development, has reached the primary endpoint in a pivotal phase 3 clinical trial
Parkinson's disease is a progressive neurodegenerative disease caused by the gradual loss of brain cells that produce the neurotransmitter dopamine
In advanced patients, oral levodopa faces a variety of challenges.
ABBV-951 is a prodrug of levodopa and carbidopa
This randomized, double-blind, active-controlled Phase 3 clinical trial enrolled approximately 130 advanced adult patients
The test results showed that at the 12th week, the "Good On" time of the ABBV-951 group increased by 2.
In terms of safety, most adverse events (AEs) in the ABBV-951 group were mild to moderate, with a serious AE rate of 8%, and a serious AE rate of 6% in the oral drug group
Reference materials:
[1] AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease.
(The original text has been deleted)
